Overview

* Artivion ( AORT ) Q3 revenue grows 18% yr/yr, beating analyst expectations

* Adjusted net income for Q3 beats analyst expectations

* Company enrolls first patient in ARTIZEN trial, marking strategic progress

Outlook

* Artivion ( AORT ) raises full-year 2025 revenue guidance to $439 mln-$445 mln

* Company expects 2025 adjusted EBITDA to grow 24%-28%

* Artivion ( AORT ) anticipates slightly positive currency impact for 2025

Result Drivers

* PRODUCT GROWTH - Revenue growth driven by 38% increase in stent grafts and 25% increase in On-X, compared to Q3 2024

* FINANCIAL RESTRUCTURING - Refinanced credit agreement to extend maturity date to 2031 and secure a more favorable interest rate

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $113.39 $110.44

Revenue mln mln (7

Analysts

)

Q3 Beat $7.90 $1.29

Adjusted mln mln (6

Net Analysts

Income )

Q3 Net $6.50

Income mln

Q3 EBIT $12.54

mln

Q3 $65.36

Operatin mln

g

Expenses

Q3 $7.06

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Artivion Inc ( AORT ) is $46.00, about 1.1% below its November 5 closing price of $46.51

* The stock recently traded at 139 times the next 12-month earnings vs. a P/E of 100 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)